| 60.72 -1.76 (-2.82%) | 10-30 12:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 73.58 | 1-year : | 85.94 |
| Resists | First : | 62.99 | Second : | 73.58 |
| Pivot price | 58.78  |
|||
| Supports | First : | 55.97 | Second : | 51.63 |
| MAs | MA(5) : | 61.47 |
MA(20) : | 57.69 |
| MA(100) : | 45.45 |
MA(250) : | 37.98 |
|
| MACD | MACD : | 1.8 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 84.7 |
D(3) : | 90.6 |
| RSI | RSI(14): 61.4 |
|||
| 52-week | High : | 62.99 | Low : | 25.36 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ATRC ] has closed below upper band by 25.1%. Bollinger Bands are 2.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 62.91 - 63.2 | 63.2 - 63.48 |
| Low: | 60.92 - 61.27 | 61.27 - 61.59 |
| Close: | 61.92 - 62.46 | 62.46 - 62.96 |
AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.
Thu, 29 Oct 2026
AtriCure, Inc. (ATRC) Stock forecasts - Yahoo Finance UK
Thu, 29 Oct 2026
AtriCure, Inc. (ATRC) Stock Forecasts - Yahoo Finance
Mon, 26 Oct 2026
AtriCure to Participate at Upcoming Investor Conferences - Yahoo Finance
Fri, 23 Oct 2026
AtriCure, Inc. Estimates – NASDAQ:ATRC - TradingView
Tue, 20 Oct 2026
AtriCure Inc (ATRC) Shares Surge 3.9% -- What GF Score of 74 Tel - GuruFocus
Sun, 04 Oct 2026
AtriCure (ATRC) Stock Gets Fair Value Bump As Analysts Weigh Procedure Growth And Risks - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 51 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 3.7 (%) |
| Held by Institutions | 105.5 (%) |
| Shares Short | 4,820 (K) |
| Shares Short P.Month | 4,140 (K) |
| EPS | 0.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.14 |
| Profit Margin | 1.8 % |
| Operating Margin | 6.2 % |
| Return on Assets (ttm) | 1.2 % |
| Return on Equity (ttm) | 2.1 % |
| Qtrly Rev. Growth | 12.8 % |
| Gross Profit (p.s.) | 8.54 |
| Sales Per Share | 11.19 |
| EBITDA (p.s.) | 0.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 65 (M) |
| Levered Free Cash Flow | 49 (M) |
| PE Ratio | 290 |
| PEG Ratio | 10 |
| Price to Book value | 6 |
| Price to Sales | 5.43 |
| Price to Cash Flow | 47.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|